CIK: 0001738053
Total reported value
$503.6M
Reporting period: 2019-12-31 · Number of holdings: 18
VHCP Management III, LLC disclosed 18 holdings in its latest 13F filing for the period ending 2019-12-31, with total reported value of $503.6M and a quarterly turnover rate of 100.0%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "V"
Sector classification currently covers about 32% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add CNST
+3674.3% $118.1M
Trim MIST
0.0% -$5.5M
Add AXSM
-3.9% $127.4M
Trim PTGX
-92.5% -$12.3M
Trim H5861P103
-30.1% -$6.6M
Trim TXG
0.0% $7.8M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | AXSM | Axsome Therapeutics INC | Stock-Healthcare | 31.77% | +11.64% | -3.93% | |
| 2 | CNST | Constellation Pharmaceutical | Stock-Other | 23.54% | +23.27% | +3674.34% | |
| 3 | MIST | Milestone Pharmaceuticals In | Stock-Other | 6.57% | -17.22% | — | |
| 4 | RLMD | Relmada Therapeutics INC | Stock-Other | 5.95% | +5.95% | NEW | |
| 5 | ETNBGBP | 89bio INC | Stock-Other | 5.00% | +5.00% | NEW | |
| 6 | TXG | 10x Genomics Inc-class A | Stock-Other | 4.54% | -4.79% | — | |
| 7 | FTSVEUR | Forty Seven INC | Stock-Other | 4.04% | +4.04% | NEW | |
| 8 | ITCIEUR | Intra-cellular Therapies INC | Stock-Other | 3.92% | +3.92% | NEW | |
| 9 | OPHTEUR | Iveric Bio INC | Stock-Other | 2.90% | +2.90% | NEW | |
| 10 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 2.19% | -2.38% | -2.82% | |
| 11 | ADVMCHF | Adverum Biotechnologies INC | Stock-Other | 2.16% | +2.16% | NEW | |
| 12 | MRNSUSD | Marinus Pharmaceuticals INC | Stock-Other | 2.15% | -0.24% | +99.36% | |
| 13 | ✓ | Mersana Therapeutics INC | Stock-Other | 1.78% | +1.78% | NEW | |
| 14 | ✓ | Myovant Sciences LTD | Stock-Other | 1.40% | +1.40% | NEW | |
| 15 | NXTCEUR | Nextcure INC | Stock-Other | 1.34% | +1.34% | NEW | |
| 16 | ✓ | Obseva SA | Stock-Other | 0.61% | -5.35% | -30.14% | |
| 17 | PTGX | Protagonist Therapeutics INC | Stock-Other | 0.11% | -7.84% | -92.45% | |
| 18 | BLPHEUR | Bellerophon Therapeutics INC | Stock-Other | 0.03% | -0.69% | -84.12% |
Not enough priced holdings yet to compute performance
VHCP Management III, LLC's most significant position changes for 2019-12-31: New buy: Relmada Therapeutics INC (RLMD); New buy: 89bio INC (ETNBGBP); New buy: Forty Seven INC (FTSVEUR); New buy: Intra-cellular Therapies INC (ITCIEUR); Sold out: Ra Pharmaceuticals INC (RARXEUR).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CNST | Constellation Pharmaceutical | +23.3% | +3674.34% | Add |
| 2 | AXSM | Axsome Therapeutics INC | +11.6% | -3.93% | Trim |
| 3 | MRNSUSD | Marinus Pharmaceuticals INC | -0.2% | +99.36% | Add |
| 4 | BLPHEUR | Bellerophon Therapeutics INC | -0.7% | -84.12% | Trim |
| 5 | 4XC1 | Kalvista Pharmaceuticals INC | -2.4% | -2.82% | Trim |
| 6 | TXG | 10x Genomics Inc-class A | -4.8% | — | Unchanged |
| 7 | ✓ | Obseva SA | -5.4% | -30.14% | Trim |
| 8 | PTGX | Protagonist Therapeutics INC | -7.8% | -92.45% | Trim |
| 9 | MIST | Milestone Pharmaceuticals In | -17.2% | — | Unchanged |
| 10 | RLMD | Relmada Therapeutics INC | — | NEW | New buy |
| 11 | ETNBGBP | 89bio INC | — | NEW | New buy |
| 12 | FTSVEUR | Forty Seven INC | — | NEW | New buy |
| 13 | ITCIEUR | Intra-cellular Therapies INC | — | NEW | New buy |
| 14 | RARXEUR | Ra Pharmaceuticals INC | — | EXIT | Sold out |
| 15 | OPHTEUR | Iveric Bio INC | — | NEW | New buy |
| 16 | LJPC | La Jolla Pharmaceutical Co | — | EXIT | Sold out |
| 17 | ADVMCHF | Adverum Biotechnologies INC | — | NEW | New buy |
| 18 | ✓ | Mersana Therapeutics INC | — | NEW | New buy |
| 19 | BCRX | Biocryst Pharmaceuticals INC | — | EXIT | Sold out |
| 20 | ✓ | Myovant Sciences LTD | — | NEW | New buy |
| 21 | NXTCEUR | Nextcure INC | — | NEW | New buy |
| 22 | 1T7 | Tricida INC | — | EXIT | Sold out |
| 23 | KNSA | Kiniksa Pharmaceuticals International, plc | — | EXIT | Sold out |
| 24 | RDUSEUR | Radius Health INC | — | EXIT | Sold out |
| 25 | PTIEUR | Proteostasis Therapeutics In | — | EXIT | Sold out |
| 26 | ✓ | Prevail Therapeutics INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2019-12-31 | 2020-02-13 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-13 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-13 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-14 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-13 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001121908
Total reported value
$503.6M
70 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001616026
Total reported value
$503.5M
719 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001950323
Total reported value
$503.9M
1,361 stks
2026-06-30
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001602263
Total reported value
$379.4M
20 stks
2019-12-31
Stale — no recent filing
2 of the top 5 holdings overlap, including Axsome Therapeutics INC
CIK 0001444117
Total reported value
$100.7M
3 stks
2020-06-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Constellation Pharmaceutical
CIK 0001549408
Total reported value
$194.9M
14 stks
2026-03-31
1 of the top 5 holdings overlap, including Axsome Therapeutics INC